ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00483132
Recruitment Status : Completed
First Posted : June 6, 2007
Last Update Posted : June 6, 2007
Sponsor:
Information provided by:
French Innovative Leukemia Organisation

Brief Summary:

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.

High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).


Condition or disease Intervention/treatment Phase
Leukemia, Lymphocytic, Acute Drug: interferon alpha 2a Phase 3

Detailed Description:
Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 232 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
Study Start Date : September 1994
Actual Study Completion Date : April 2002





Primary Outcome Measures :
  1. overall survival [ Time Frame: time to death ]

Secondary Outcome Measures :
  1. Efficacy of study treatments [ Time Frame: time to end of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • ALL high risk or low risk or lymphoblastic lymphoma
  • age 15-55 years old
  • informed consent signed

Exclusion Criteria:

  • patients previously treated with a chemotherapy or alpha-interferon
  • ALL 3 (burkitt like)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483132


Locations
France
INorbert IFRAH
Angers, chu ANGERS, France, 49000
Sponsors and Collaborators
French Innovative Leukemia Organisation
Investigators
Principal Investigator: Norbert IFRAH, Pr French Innovative Leukemia Organisation
Principal Investigator: Noël MILPIED French Innovative Leukemia Organisation

Publications of Results:
ClinicalTrials.gov Identifier: NCT00483132     History of Changes
Other Study ID Numbers: GOELAL02
First Posted: June 6, 2007    Key Record Dates
Last Update Posted: June 6, 2007
Last Verified: June 2007

Additional relevant MeSH terms:
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Interferons
Interferon-alpha
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs